



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/712,073	11/13/2003	Beth E. Drees	007262-30 US	7922
36234 7590 06/13/2008 THE MCCALLUM LAW FIRM, P. C. 685 BRIGGS STREET PO BOX 929 ERIE, CO 80516				
EXAMINER				
COUNTS, GARY W				
ART UNIT		PAPER NUMBER		
1641				
MAIL DATE		DELIVERY MODE		
06/13/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/712,073

Applicant(s)

DREES ET AL.

Examiner

GARY W. COUNTS

Art Unit

1641

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 March 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-15, 32-34 and 38 is/are pending in the application.
- 4a) Of the above claim(s) 5, 6 and 9 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4, 7, 8, 10-15, 32-34 and 38 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Status of the claims

Applicant's amendments filed March 21, 2008 is acknowledged and has been entered. Currently, claims 1-15, 32-34, and 38 are pending. Claims 5, 6 and 9 are withdrawn as being directed to non-elected species. Claims 1-4, 7, 8, 10-15, 32-34 and 38 are under examination.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 32-34 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Enablement requires that the specification teach those in the art to make and use the invention without undue experimentation. The factors that must be considered in determining undue experimentation are set forth in *In re Wands* USPTQ2d 14000. Factors to be considered in determining whether a disclosure would require undue experimentation include (1) the nature of the invention, (2) the state of the prior art, (3) the predictability or lack thereof in the art, (4) the amount of direction or guidance present, (5) the presence or absence of

working examples, (6) the quantity of experimentation necessary, (7) the relative skill of those in the art, and (8) the breadth of the claims.

The instant claims are directed to a method of screening a disease caused alteration of a lipid phosphatase comprising the step of using the lipid phosphates assay method of claim 1 to detect changes in the lipid phosphatase activity in bodily tissue, blood or serum samples, whereby detection of a change indicates a disease caused alteration of a lipid phosphatase. The specification on page 2 under the section entitled background of the invention, the applicant discloses that lipid phosphatases and alterations in their activity levels are implicated in a variety of signaling pathways that are important in regulation of insulin sensitivity and allergic and immune responses, and which are altered in carcinogenesis. The specification on page 8, lines 21-26 discloses that the signaling pathways involving these lipid modifying enzymes are often perturbed in the events leading to disease, particularly in non-insulin dependent diabetes mellitus and cancer. The specification further discloses that the tools developed in the present invention have significant value for research and in diagnostic applications. The specification on page 9, lines 27-29 discloses that the lipid phosphatase assay is a screening method for disease detection, i.e. Cowden's disease, and a molecule for treating such disease by detection of alteration of lipid phosphatase activity. The specification on page 10, lines 13-15 discloses that the lipid phosphatase assay can be used as a screening method for detection of a disease by detection of a predetermined level of the $PI(3,4)P_2$ or $PI(4,5)P_2$ lipid. The applicant has not disclosed how one skilled in the art can use just single determination of a change of lipid phosphatase activity and

Art Unit: 1641

have it correlated with only disease. The specification does not provide working examples, controls or standards or guidance on how a change in lipid phosphatase indicates only disease caused alteration of a lipid phosphatase. Komazawa et al (Nature Medicine, Vol 10, No. 11, 2004, pgs 1208-1215) teaches that the expression levels of PTEN protein (lipid phosphatase) are significantly increased in obesity (e.g. abstract, p. 1211) and decreased in exposure to cold (abstract, p. 1211). Bhashyam et al., (Am J Physiol Heart Circ Physiol, Vol 293 pgs H3063 –H3071) teaches the increased expression of PTEN (lipid phosphatase) in cardiac muscle in older dogs but not in skeletal muscle (e.g. p. H3067). Bhashyam et al also teaches that increased PTEN (lipid phosphatase) activity in the hearts of young dogs with dilated cardiomyopathy (e.g. p. H3068). Further, it is unclear if the change of activity involves both increases and decreases of lipid phosphatase is indicative of a disease caused alteration of a lipid phosphatase. The specification on page 4, lines 1-2 disclose that ablation of SHIP1 in transgenic mice leads to chronic hyperplasia and increased proliferation and survival of hematopoietic cells. One of ordinary skill in the art would understand that this is a decreased lipid phosphatase activity. The specification on page 4, lines 33-34 discloses that a loss of PTEN activity results in accumulation of $PI(3,4,5)P_3$. Thus, it appears that only decreases of lipid phosphatase may be correlated with disease. However, the specification does not provide for differentiating lipid phosphatase activity in disease from that of age, temperature or obesity. Such is not seen as sufficient to support the breadth of the claims and one skilled in the art cannot practice the claimed invention without undue experimentation, because in order to establish if the lipid phosphatase

Art Unit: 1641

activity indicates a disease caused alteration of lipid phosphatase, one skilled in the art would not be able to differentiate if the lipid phosphatase alteration is caused by obesity, age, temperature or disease, and one skilled would not have a high level of predictability.

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 1-4, 7, 8, 10-15, 32-34 and 38 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 4 the recitation "other lipid-binding domain" is vague and indefinite. The specification does not provide a definition for the term "other lipid-binding domains" and it is unclear what applicant is referring to.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

6. Claims 1-4, 7, 10, 11, 14, 15 and 38 are rejected under 35 U.S.C. 102(a) as being anticipated by Dowler et al (WO 02/12276).

Dowler et al disclose methods for detecting or quantifying enzyme activity such as lipid phosphatases (p. 34 & pages 130-135). Dowler et al disclose exposing a protein (lipid detector protein) that binds specifically to product lipids. Dowler et al discloses that the protein comprise a PH domain (lipid recognition motif) which is specific for product lipids (p. 130). Dowler et al disclose exposing the protein (lipid detector protein) comprising the PH domain to substrate lipid and sample and determining if the protein bound to a product lipid. Dowler et al disclose that the PH domain may be in the form of a fusion protein or that the PH domain may be tagged (p.130 & p.132). Dowler et al disclose that the method can comprise the substrate lipid in free solution (p. 133-134). Dowler et al disclose that prior to contacting that a microtiter plate surface can be coated with lipid substrate that comprises a chromophore (p. 131). Dowler et al disclose that the method may be used for making real time measurement throughout the course of the reaction (p. 132, lines 12-20). Dowler et al disclose that a FRET assay (fluorogenic assay) can be used to determine the enzyme activity. Dowler et al disclose that the substrate lipid can be immobilized or free in solution. Dowler et al disclose that the substrate lipids can be $PI(3,4,5)P_3$ or $PI(4,5)P_2$ and the product lipid $PI(4)P$ (p. 131). Dowler et al disclose that the method may be used to identify modulators of lipid phosphatase activity (p. 34, lines 21-28) by measuring lipid phosphatase activity in the presence and absence of a compound.

With respect to the recitation "wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said product lipid is present in said solution". Dowler et al teaches determining the level of activity and teaches the

Art Unit: 1641

method may be used in real time measurement throughout the course of the reaction and it is inherent that when the enzyme activity reacts upon the substrate lipid that there is an increase in the amount of product lipid in the assay. Thus, Dowler et al reads on the instantly recited claim.

Claim Rejections - 35 USC § 103

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

8. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

9. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

Art Unit: 1641

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

10. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Dowler et al (WO 02/12276) in view of Goueli et al (US 6,720,162).

See above for the teachings of Dowler et al.

Dowler et al differ from the instant invention in failing to teach the plate is coated with streptavidin.

Goueli et al teaches method for determining lipid phosphatase activity. Goueli et al disclose coating a plate with streptavidin used in assays for lipid phosphatase activity (col 3 & col 9). Goueli et al disclose that this provides for an easy means to separate the products of an enzymatic reaction from unreacted reactant, enzyme and other nonproduct ingredients of a reaction solution (col 2).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate coated streptavidin and biotin systems as taught by Goueli et al into the methods of Dowler et al because Goueli et al teaches that this provides for an easy means to separate the products of an enzymatic reaction from unreacted reactant, enzyme and other nonproduct ingredients of a reaction solution. Further, the use of streptavidin to immobilize reactants of assays is very well known in the art.

Art Unit: 1641

11. Claims 12 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dowler et al in view of Taylor et al (Analytical Biochemistry, 295, 122-126, 2001).

See above for the teachings of Dowler et al.

Dowler et al differs from the instant invention in failing to teach the lipid phosphatase is myotubularin or PTEN. Dowler et al also fails to specifically state that the sample has additional lipids.

Taylor et al disclose assays for determining phosphoinositide phosphatases such as myotubularin and PTEN which act on phosphoinositide phosphates in samples. Taylor et al disclose that the sample can have different lipids. Taylor et al teaches that these enzymes are studied to better understand their role in the synthesis, breakdown, and interconversion of inositol lipids.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate or determine myotubularin and PTEN activity as taught by Taylor et al into the method of Dowler et al because Dowler et al is generic with respect to the lipid phosphatases to be determined and Taylor et al teaches that the determination of myotubularin and PTEN which act on phosphoinositide phosphates in samples provides for a better understanding of their role in the synthesis, breakdown, and interconversion of inositol lipids.

Double Patenting

12. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory

Art Unit: 1641

obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

13. Claims 1-4, 7, 8, 10-12, 14 and 15 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-17 of copending Application No. 10/850,833. Although the conflicting claims are not identical, they are not patentably distinct from each other because each teaches assaying a lipid phosphatase by exposing a lipid recognition protein to a sample. Also, both inventions require a lipid substrate and it would have been obvious to one of ordinary skill in the art that the claims of 10/850833 requiring quantifying the lipid product would also encompass the claims of application 10/712,073.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Response to Arguments

14. Applicant's arguments filed 03/21/08 have been fully considered but they are not persuasive.

112 2nd rejections

Applicant argues that the recitation "other lipid-binding domains" is not vague and indefinite. Applicant directs Examiner's attention to page 8, line 21 which reads that "the signaling pathways involving these lipid modifying enzyme..." Applicant states that upon reading this disclosure, one of ordinary skill in the art would understand that "other lipid-binding domains" refers to those which are capable of interacting with lipids. Applicant also states that one of ordinary skill in the art would understand which particular functional groups need to be present in the domain for a reaction or interaction to occur with the lipid. Applicant further directs the Examiner's attention to page 10 lines 3-4 which describes that "...proteins that are specific for PI(3,4)P₂ or PI(4,5)P₂ can be used in accordance with the invention.". These arguments are not found persuasive because limitations from the specification are not read into the claims. Further, the passages referred to by the applicant do not make clear what is meant by "other lipid binding domains" as stated above applicant has not provided a definition for the term in the specification and it is unclear what applicant intends or is trying to encompass. The disclosure does not provide a definition for the term nor any guidance of any type for what is considered to be or what might be considered "other lipid binding domains".

102 rejections

Applicant argues that Dowler et al describes a method wherein a substrate lipid is incubated with an appropriate enzyme in the presence of a PH domain fused green fluorescent protein. Applicant directs Examiners attention to page 131, lines 24-28.

Applicant states that as such, Dowler et al does not disclose exposing a lipid detector protein to a solution contain a substrate lipid and lipid phosphatase. This is not found persuasive because Dowler et al specifically teaches that the substrate lipid can be free in solution (see above and previous office action). One skilled in the art would recognize that the substrate lipid of the solution would be contacted with the lipid detector protein. Further, the claim does not require the solution to comprise the lipid phosphatase.

103 rejections

Applicant argues that Dowler et al does not describe contacting a lipid detector protein to a solution containing a substrate lipid of a lipid phosphatase as provided in claim 1 and that Goueli et al does not disclose this claim limitation either. This is not found persuasive because of reasons stated above that Dowler does teach such a limitation. Thus, the combination of Dowler et al and Goueli et al is considered appropriate and still reads on the instantly recited claims.

Applicant argues that Dowler et al does not describe contacting a lipid detector protein to a solution containing a substrate lipid of a lipid phosphatase as provided in claim 1 and that Taylor et al does not disclose this claim limitation either. This is not found persuasive because of reasons stated above that Dowler does teach such a limitation. Thus, the combination of Dowler et al and Taylor et al is considered appropriate and still reads on the instantly recited claims.

Conclusion

15. No claims are allowed.
16. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to GARY W. COUNTS whose telephone number is (571)272-0817. The examiner can normally be reached on M-F 8:00 - 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/ Gary W. Counts/
Examiner, Art Unit 1641

/Long V Le/
Supervisory Patent Examiner, Art Unit 1641